SARTORIUS STEDIM BIOTECH (56S1.DE) Stock Fundamental Analysis
Europe - FRA:56S1 - FR0013154002 - Common Stock
195.5 EUR
+1.85 (+0.96%)
Taking everything into account, 56S1 scores 5 out of 10 in our fundamental rating. 56S1 was compared to 18 industry peers in the Life Sciences Tools & Services industry. 56S1 has an average financial health and profitability rating. 56S1 is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
56S1 had positive earnings in the past year.
In the past year 56S1 had a positive cash flow from operations.
56S1 had positive earnings in each of the past 5 years.
Each year in the past 5 years 56S1 had a positive operating cash flow.
1.2 Ratios
56S1 has a Return On Assets of 3.35%. This is in the lower half of the industry: 56S1 underperforms 66.67% of its industry peers.
56S1 has a worse Return On Equity (6.54%) than 66.67% of its industry peers.
With a Return On Invested Capital value of 5.94%, 56S1 perfoms like the industry average, outperforming 44.44% of the companies in the same industry.
56S1 had an Average Return On Invested Capital over the past 3 years of 10.41%. This is above the industry average of 7.57%.
The 3 year average ROIC (10.41%) for 56S1 is well above the current ROIC(5.94%). The reason for the recent decline needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROIC | 5.94% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
1.3 Margins
Looking at the Profit Margin, with a value of 8.96%, 56S1 is in line with its industry, outperforming 55.56% of the companies in the same industry.
56S1's Profit Margin has declined in the last couple of years.
56S1 has a Operating Margin of 16.63%. This is in the better half of the industry: 56S1 outperforms 61.11% of its industry peers.
56S1's Operating Margin has declined in the last couple of years.
With a decent Gross Margin value of 45.64%, 56S1 is doing good in the industry, outperforming 61.11% of the companies in the same industry.
56S1's Gross Margin has declined in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% |
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so 56S1 is still creating some value.
56S1 has more shares outstanding than it did 1 year ago.
56S1 has more shares outstanding than it did 5 years ago.
56S1 has a better debt/assets ratio than last year.
2.2 Solvency
56S1 has an Altman-Z score of 4.27. This indicates that 56S1 is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 4.27, 56S1 belongs to the top of the industry, outperforming 88.89% of the companies in the same industry.
The Debt to FCF ratio of 56S1 is 6.84, which is on the high side as it means it would take 56S1, 6.84 years of fcf income to pay off all of its debts.
56S1 has a Debt to FCF ratio (6.84) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.50 indicates that 56S1 is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.50, 56S1 is in line with its industry, outperforming 50.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Altman-Z | 4.27 |
ROIC/WACC0.7
WACC8.5%
2.3 Liquidity
56S1 has a Current Ratio of 1.05. This is a normal value and indicates that 56S1 is financially healthy and should not expect problems in meeting its short term obligations.
56S1 has a Current ratio of 1.05. This is in the lower half of the industry: 56S1 underperforms 72.22% of its industry peers.
56S1 has a Quick Ratio of 1.05. This is a bad value and indicates that 56S1 is not financially healthy enough and could expect problems in meeting its short term obligations.
56S1 has a Quick ratio of 0.50. This is amonst the worse of the industry: 56S1 underperforms 83.33% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.11% over the past year.
The Earnings Per Share has been growing slightly by 4.19% on average over the past years.
56S1 shows a small growth in Revenue. In the last year, the Revenue has grown by 7.72%.
The Revenue has been growing by 14.05% on average over the past years. This is quite good.
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
3.2 Future
56S1 is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.23% yearly.
56S1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 10.45% yearly.
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
With a Price/Earnings ratio of 45.36, 56S1 can be considered very expensive at the moment.
Based on the Price/Earnings ratio, 56S1 is valued more expensive than 83.33% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 25.67. 56S1 is valued rather expensively when compared to this.
Based on the Price/Forward Earnings ratio of 36.43, the valuation of 56S1 can be described as expensive.
56S1's Price/Forward Earnings ratio is a bit more expensive when compared to the industry. 56S1 is more expensive than 77.78% of the companies in the same industry.
56S1's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 31.86.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.36 | ||
| Fwd PE | 36.43 |
4.2 Price Multiples
56S1's Enterprise Value to EBITDA ratio is rather expensive when compared to the industry. 56S1 is more expensive than 83.33% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, 56S1 is valued a bit more expensive than the industry average as 61.11% of the companies are valued more cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 50.81 | ||
| EV/EBITDA | 26.36 |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
56S1's earnings are expected to grow with 23.30% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.64
PEG (5Y)10.81
EPS Next 2Y23.83%
EPS Next 3Y23.3%
5. Dividend
5.1 Amount
56S1 has a yearly dividend return of 0.33%, which is pretty low.
Compared to an average industry Dividend Yield of 0.72, 56S1 has a dividend in line with its industry peers.
Compared to an average S&P500 Dividend Yield of 2.40, 56S1's dividend is way lower than the S&P500 average.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
5.2 History
The dividend of 56S1 has a limited annual growth rate of 4.44%.
Dividend Growth(5Y)4.44%
Div Incr Years0
Div Non Decr Years1
5.3 Sustainability
25.41% of the earnings are spent on dividend by 56S1. This is a low number and sustainable payout ratio.
The dividend of 56S1 is growing, but earnings are growing more, so the dividend growth is sustainable.
DP25.41%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
FRA:56S1 (11/6/2025, 7:00:00 PM)
195.5
+1.85 (+0.96%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners11.07%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.03B
Revenue(TTM)2.95B
Net Income(TTM)264.10M
Analysts81.11
Price Target239.05 (22.28%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0.33% |
Yearly Dividend0.71
Dividend Growth(5Y)4.44%
DP25.41%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)3.99%
Min EPS beat(2)-2.24%
Max EPS beat(2)10.22%
EPS beat(4)3
Avg EPS beat(4)9.45%
Min EPS beat(4)-2.24%
Max EPS beat(4)22.18%
EPS beat(8)3
Avg EPS beat(8)-1.58%
EPS beat(12)3
Avg EPS beat(12)-11.08%
EPS beat(16)4
Avg EPS beat(16)-13.1%
Revenue beat(2)1
Avg Revenue beat(2)-1.82%
Min Revenue beat(2)-3.94%
Max Revenue beat(2)0.3%
Revenue beat(4)3
Avg Revenue beat(4)0.7%
Min Revenue beat(4)-3.94%
Max Revenue beat(4)3.52%
Revenue beat(8)5
Avg Revenue beat(8)-0.23%
Revenue beat(12)5
Avg Revenue beat(12)-1.54%
Revenue beat(16)7
Avg Revenue beat(16)-0.72%
PT rev (1m)-0.17%
PT rev (3m)-1.57%
EPS NQ rev (1m)9.76%
EPS NQ rev (3m)9.76%
EPS NY rev (1m)0%
EPS NY rev (3m)2.93%
Revenue NQ rev (1m)0.11%
Revenue NQ rev (3m)5.19%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.33%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 45.36 | ||
| Fwd PE | 36.43 | ||
| P/S | 6.46 | ||
| P/FCF | 50.81 | ||
| P/OCF | 26.04 | ||
| P/B | 4.71 | ||
| P/tB | N/A | ||
| EV/EBITDA | 26.36 |
EPS(TTM)4.31
EY2.2%
EPS(NY)5.37
Fwd EY2.75%
FCF(TTM)3.85
FCFY1.97%
OCF(TTM)7.51
OCFY3.84%
SpS30.27
BVpS41.47
TBVpS-4.02
PEG (NY)1.64
PEG (5Y)10.81
Graham Number63.42
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 3.35% | ||
| ROE | 6.54% | ||
| ROCE | 7.46% | ||
| ROIC | 5.94% | ||
| ROICexc | 6.26% | ||
| ROICexgc | 21.64% | ||
| OM | 16.63% | ||
| PM (TTM) | 8.96% | ||
| GM | 45.64% | ||
| FCFM | 12.71% |
ROA(3y)7.81%
ROA(5y)9.13%
ROE(3y)17.3%
ROE(5y)20.06%
ROIC(3y)10.41%
ROIC(5y)14.57%
ROICexc(3y)10.84%
ROICexc(5y)15.37%
ROICexgc(3y)26.31%
ROICexgc(5y)36.49%
ROCE(3y)13.07%
ROCE(5y)18.3%
ROICexgc growth 3Y-36.77%
ROICexgc growth 5Y-16.49%
ROICexc growth 3Y-43.34%
ROICexc growth 5Y-25.09%
OM growth 3Y-22.38%
OM growth 5Y-9.98%
PM growth 3Y-24.01%
PM growth 5Y-17.3%
GM growth 3Y-6.9%
GM growth 5Y-3.53%
F-Score8
Asset Turnover0.37
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.5 | ||
| Debt/FCF | 6.84 | ||
| Debt/EBITDA | 2.5 | ||
| Cap/Depr | 113.12% | ||
| Cap/Sales | 12.09% | ||
| Interest Coverage | 3.09 | ||
| Cash Conversion | 90.78% | ||
| Profit Quality | 141.8% | ||
| Current Ratio | 1.05 | ||
| Quick Ratio | 0.5 | ||
| Altman-Z | 4.27 |
F-Score8
WACC8.5%
ROIC/WACC0.7
Cap/Depr(3y)182.98%
Cap/Depr(5y)186.68%
Cap/Sales(3y)13.87%
Cap/Sales(5y)12.23%
Profit Quality(3y)126.76%
Profit Quality(5y)109.63%
High Growth Momentum
Growth
EPS 1Y (TTM)35.11%
EPS 3Y-22.3%
EPS 5Y4.19%
EPS Q2Q%23.68%
EPS Next Y27.61%
EPS Next 2Y23.83%
EPS Next 3Y23.3%
EPS Next 5Y22.23%
Revenue 1Y (TTM)7.72%
Revenue growth 3Y-1.25%
Revenue growth 5Y14.05%
Sales Q2Q%7.67%
Revenue Next Year9.03%
Revenue Next 2Y9.51%
Revenue Next 3Y10.23%
Revenue Next 5Y10.45%
EBIT growth 1Y25.54%
EBIT growth 3Y-23.35%
EBIT growth 5Y2.67%
EBIT Next Year92.67%
EBIT Next 3Y37.11%
EBIT Next 5Y27.7%
FCF growth 1Y219.27%
FCF growth 3Y7.94%
FCF growth 5Y22.24%
OCF growth 1Y15.97%
OCF growth 3Y5.11%
OCF growth 5Y21.32%
SARTORIUS STEDIM BIOTECH / 56S1.DE FAQ
What is the ChartMill fundamental rating of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a fundamental rating of 5 / 10 to 56S1.DE.
What is the valuation status of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to SARTORIUS STEDIM BIOTECH (56S1.DE). This can be considered as Overvalued.
Can you provide the profitability details for SARTORIUS STEDIM BIOTECH?
SARTORIUS STEDIM BIOTECH (56S1.DE) has a profitability rating of 5 / 10.
What is the financial health of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The financial health rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 4 / 10.
How sustainable is the dividend of SARTORIUS STEDIM BIOTECH (56S1.DE) stock?
The dividend rating of SARTORIUS STEDIM BIOTECH (56S1.DE) is 3 / 10 and the dividend payout ratio is 25.41%.